Canaccord Calls AbbVie a Core Holding With a $262 Target: Is This Biopharma’s Most Durable Compounder?

One of Wall Street’s top firms just made the bull case for AbbVie (NYSE:ABBV | ABBV Price Prediction) stock, initiating coverage with a Buy rating and a $262 price target. Canaccord calls AbbVie a “core holding” for large-cap biopharma investors, pointing to a “solid and visible” growth profile underpinned by three distinct franchise pillars. With shares trading near $205, the initiation arrives at a moment when the stock sits well below its 52-week high of $239.13.

The timing matters. AbbVie delivered full-year 2025 revenue of $61.16 billion, up 9% year-over-year, and management is guiding for adjusted diluted EPS of $14.37 to $14.57 in 2026. That kind of visible earnings acceleration is exactly what Canaccord is betting on.

AbbVie CEO Robert A. Michael put it directly: “Based on our strong fundamentals, we expect another year of robust growth in 2026. This momentum combined with our investments in innovation position AbbVie for long-term success.”

The Analyst’s Case

Canaccord’s initiation rests on three pillars. First, the firm calls AbbVie’s Immunology franchise “best-in-class.” That’s hard to argue with: the immunology segment generated $8.63 billion in Q4 2025, up 18% year-over-year, powered by Skyrizi at $5.01 billion (+33%) and Rinvoq at $2.37 billion (+30%).

Second, Canaccord sees the neuroscience franchise as “underappreciated.” The segment posted $2.96 billion in Q4, up 18% year-over-year, with migraine therapies showing exceptional momentum. Third, the firm points to optionality in AbbVie’s oncology pipeline as a potential upside catalyst that the market hasn’t fully priced in.

Why the Move Matters Now

AbbVie stock is down 10% year-to-date, creating what Canaccord appears to view as an attractive entry point relative to the company’s earnings trajectory. The broader analyst community leans constructive: 22 analysts rate the stock Buy or Strong Buy, with just 9 at Hold and zero Sell ratings. The consensus price target sits at $249, making Canaccord’s $262 target among the more bullish on the Street.

AbbVie’s forward P/E ratio of 14x looks reasonable for a company guiding toward meaningful EPS acceleration, especially one with a dividend that’s been raised every year since its 2013 spinoff from Abbott Laboratories. The quarterly dividend currently stands at $1.73 per share, up from $1.64 in 2025, representing a 6% increase. That kind of consistent income growth resonates with dividend investors who rely on steady compounding.

What It Means for Your Portfolio

For retirement-focused investors, AbbVie’s combination of a growing dividend, a diversified biopharma platform, and a visible earnings ramp makes it worth serious consideration. The key risks to monitor include ongoing Humira biosimilar erosion, Imbruvica’s continued decline (-21% in Q4), softness in the Aesthetics segment, and the potential impact of pharmaceutical tariffs.

You should also watch for whether AbbVie’s oncology pipeline developments deliver the upside optionality Canaccord is counting on. If they do, the $262 target starts to look well-supported. If pipeline execution disappoints, the near-term growth story gets murkier.

All in all, Canaccord’s initiation adds a credible institutional voice to what’s already a broadly bullish analyst consensus on AbbVie stock. The company’s track record of navigating the post-Humira transition — delivering record net sales in just the second full year following U.S. loss of exclusivity — suggests management has earned the benefit of the doubt on execution. For long-term investors, that combination of income, growth, and pipeline optionality is a compelling mix.